A LinkedIn post from Okami Medical highlights the company’s planned presence at GEST 2026 in New York, a conference focused on endovascular therapies. The post promotes the LOBO HDBRAID Vascular Occluder, described as the first and only device designed for complete vascular occlusion with an emphasis on deliverability and stability in complex peripheral embolization cases.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
According to the post, Okami Medical intends to showcase the device at Booth 114 and participate in educational programming, including a hands-on workshop on coils and plugs and a masterclass on plugs and stent grafts. The company’s visibility at a specialized interventional radiology meeting may support physician awareness and adoption of LOBO technology, which could be important for procedure volume growth and future revenue.
For investors, the emphasis on complex-case navigation suggests Okami Medical is positioning its product for high-acuity indications, potentially targeting a differentiated niche within vascular occlusion. Engagement in workshops and masterclasses may also indicate a strategy to build clinical credibility and deepen relationships with key opinion leaders, factors that can influence hospital purchasing decisions and long-term competitive positioning in the peripheral embolization market.